Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Atea Pharmaceuticals (NASDAQ: AVIR ) stock is on the move Tuesday after providing an update from its Phase 2 Moonsong clinical trial update. Source: Shutterstock The Moonsong trial was evaluating the effectiv...
Atea Pharmaceuticals (NASDAQ:AVIR) -76% after mid-stage AT-527 COVID-19 trial fails to meet main goal. Galera Therapeutics (NASDAQ:GRTX) -72% after results of late-stage ROMAN trial of avasopasem for radiotherapy-induced severe oral mucositis Valneva (NASDAQ:VALN) -8%. ION Geop...
Topline Phase 2 MOONSONG trial results did not meet the primary endpoint in the overall population of patients with mild or moderate COVID-19, who were mostly low-risk with mild symptoms In high-risk patients with underlying health conditions, a reduction of viral load of ...
COVID-19 has radically transformed the valuations of vaccines in the stock market. Novavax has jumped from $4 a share to $164. Moderna has run up from $19 to $304. The vaccine stocks have run up the most because that subsector is still our best hope for defeating COVID-19 once and f...
BOSTON, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will present analyses confirming data previously reported relating to the AT-527 COVID-19 clinical trial program at...
COVID-19 pills are going to be a big deal. Even though healthcare professionals aren't quite sure how these medications will be used yet, Wall Street already expects Merck 's (NYSE: MRK) and Ridgeback Biotherapeutics' oral antiviral drug molnupiravir, which produced stellar late...
4 Top Health Care Stocks To Consider Buying [Or Selling] This Week Health care stocks have been some of the hottest stocks to buy in the stock market over the past few years. Well, the global pandemic certainly reminded us how fragile life could be. On Friday, the worldwide ...
On Friday we saw a major sell-off in COVID vaccine stocks. Novavax (NASDAQ: NVAX) dropped 12%, and shares of Moderna (NASDAQ: MRNA) fell 11%. Meanwhile, another healthcare sector was soaring: stocks with oral treatments for COVID. Shares of Merck (NYSE: MRK) ran ...
Welcome to the "Merck Cures COVID!" edition of Hot Stocks. Of course, the drug maker didn't actually cure the disease. But it did release blockbuster clinical-trial data for an anti-COVID pill that contributed to an overall Wall Street rally. Many segments of the market took the MRK anno...
With the biggest gain since at least 2016, Merck (MRK +8.8%) hit a 52-week high in reaction to promising early data posted with its partner Ridgeback Biotherapeutics, for the oral COVID-19 therapy, molnupiravir. In an interim analysis of a late-stage trial involving patients with mild-to-mode...
News, Short Squeeze, Breakout and More Instantly...
Atea Pharmaceuticals Inc. Company Name:
AVIR Stock Symbol:
NASDAQ Market:
Atea Pharmaceuticals Inc. Website:
97% SVR12 Rate Observed with 8 Weeks of Treatment in Lead-In Cohort of HCV-Infected Patients in Ongoing Phase 2 Clinical Study EASL Presentations Continue to Support Best-in-Class Potential with High Antiviral Potency, Short Treatment Duration, Low Risk of Drug Interaction and High Barr...
Presentations to Include New Antiviral Efficacy Results, Including SVR12 Data, from Lead-In Cohort of Ongoing Phase 2 HCV Trial Data Also Highlight the High Prevalence of Pre-Existing NS5A Resistance-Associated Substitutions (RAS) Detected in HCV-infected Patients BOSTON, May 22, 20...
Full Enrollment Achieved in Global Phase 3 SUNRISE-3 Trial for Treatment of COVID-19 with Results Expected 2H’24 Global Phase 2 HCV Study On Track to Report Complete SVR12 Results 2H’24 Multiple Presentations Showcasing Preclinical and New Phase 2 Efficacy Data to ...